JP2017524366A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524366A5
JP2017524366A5 JP2017507848A JP2017507848A JP2017524366A5 JP 2017524366 A5 JP2017524366 A5 JP 2017524366A5 JP 2017507848 A JP2017507848 A JP 2017507848A JP 2017507848 A JP2017507848 A JP 2017507848A JP 2017524366 A5 JP2017524366 A5 JP 2017524366A5
Authority
JP
Japan
Prior art keywords
protein
factor
furin
transformed
transformed cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017507848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524366A (ja
JP6793114B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/044883 external-priority patent/WO2016025615A1/en
Publication of JP2017524366A publication Critical patent/JP2017524366A/ja
Publication of JP2017524366A5 publication Critical patent/JP2017524366A5/ja
Application granted granted Critical
Publication of JP6793114B2 publication Critical patent/JP6793114B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017507848A 2014-08-12 2015-08-12 フューリンを分泌する哺乳動物の発現系における、完全に処理され機能的な第x因子の産生 Active JP6793114B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036438P 2014-08-12 2014-08-12
US62/036,438 2014-08-12
PCT/US2015/044883 WO2016025615A1 (en) 2014-08-12 2015-08-12 Production of fully processed and functional factor x in a furin-secreting mammalian expression system

Publications (3)

Publication Number Publication Date
JP2017524366A JP2017524366A (ja) 2017-08-31
JP2017524366A5 true JP2017524366A5 (cg-RX-API-DMAC7.html) 2018-09-27
JP6793114B2 JP6793114B2 (ja) 2020-12-09

Family

ID=54035298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507848A Active JP6793114B2 (ja) 2014-08-12 2015-08-12 フューリンを分泌する哺乳動物の発現系における、完全に処理され機能的な第x因子の産生

Country Status (14)

Country Link
US (1) US9873892B2 (cg-RX-API-DMAC7.html)
EP (1) EP3180427B1 (cg-RX-API-DMAC7.html)
JP (1) JP6793114B2 (cg-RX-API-DMAC7.html)
CN (1) CN107002041B (cg-RX-API-DMAC7.html)
AR (1) AR102048A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015301726B2 (cg-RX-API-DMAC7.html)
CA (1) CA2958056C (cg-RX-API-DMAC7.html)
EA (1) EA035444B1 (cg-RX-API-DMAC7.html)
ES (1) ES2742724T3 (cg-RX-API-DMAC7.html)
IL (1) IL250530B (cg-RX-API-DMAC7.html)
MX (1) MX377236B (cg-RX-API-DMAC7.html)
NZ (1) NZ729729A (cg-RX-API-DMAC7.html)
TW (1) TWI666319B (cg-RX-API-DMAC7.html)
WO (1) WO2016025615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US11299533B2 (en) 2017-06-23 2022-04-12 Takeda Pharmaceutical Company Limited Purification of factor VIII subspecies
WO2020257942A1 (en) * 2019-06-28 2020-12-30 Peel Sean A F A method for increasing yields and the specific activity of certain recombinant proteins in mammalian cells by co-expressing full-length furin
GB202018320D0 (en) * 2020-11-20 2021-01-06 Univ Newcastle Methods of producing recombinant complement proteins
WO2023141754A1 (zh) * 2022-01-25 2023-08-03 青岛万明赛伯药业有限公司 proNGF突变体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0574402B2 (en) 1990-11-26 2012-08-01 Genetics Institute, LLC Expression of pace in host cells and methods of use thereof
AT404838B (de) * 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
JPH09295945A (ja) * 1996-04-30 1997-11-18 Hoechst Yakuhin Kogyo Kk 成熟型骨誘導因子の製造方法
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
AU784195B2 (en) 1999-11-12 2006-02-16 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
US7223390B2 (en) * 2003-05-09 2007-05-29 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
EP1969127B8 (en) * 2005-12-21 2017-12-13 Aptevo BioTherapeutics LLC Method of producing biologically active vitamin k dependent proteins by recombinant methods
KR101156263B1 (ko) 2007-05-18 2012-06-13 박스터 헬쓰케어 에스.에이. 폰 빌리브란트 인자 프로펩티드로부터 성숙한 폰 빌리브란트 인자를 제조하는 방법
WO2009088713A1 (en) * 2007-12-31 2009-07-16 Baxter International Inc. Substantially animal protein-free recombinant furin and methods for producing same
JP5843357B2 (ja) 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
CA2837948C (en) 2011-06-02 2018-08-21 Baxter International Inc. Formulations of recombinant furin

Similar Documents

Publication Publication Date Title
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
IL259120A (en) Her2-targeted antigen chimeric receptors2
JP2017524366A5 (cg-RX-API-DMAC7.html)
MX2023009050A (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas.
WO2016092550A3 (en) Methods of producing long acting ctp-modified polypeptides
NZ751946A (en) Rna-guided nucleic acid modifying enzymes and methods of use thereof
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
MX376623B (es) Cultivo celular metabolicamente optimizado.
MY205245A (en) Scalable method for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
IL292650B1 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
HK1214739A1 (zh) 工程化的分泌蛋白质和方法
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
JP2010518833A5 (cg-RX-API-DMAC7.html)
SG10201809152QA (en) Recombinant host cell for expressing proteins of interest
JP2016105737A5 (cg-RX-API-DMAC7.html)
ATE481483T1 (de) Verfahren zur herstellung eines rekombinanten polyklonalen proteins
IN2014DN03419A (cg-RX-API-DMAC7.html)
WO2011091350A3 (en) Methods & compositions for improving protein production
JP2020509751A5 (cg-RX-API-DMAC7.html)
JP2019514399A5 (cg-RX-API-DMAC7.html)
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
JP2018507204A5 (cg-RX-API-DMAC7.html)
JP2016500260A5 (cg-RX-API-DMAC7.html)